Latest & greatest articles for fluticasone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluticasone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluticasone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluticasone

101. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma

Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily (...) and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback B, Jenkins C, Price M J, Thwaites R M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Salmeterol/fluticasone propionate combination

2000 NHS Economic Evaluation Database.

102. Cost effectiveness of inhaled fluticasone propionate vs inhaled triamcinolone acetonide in the treatment of persistent asthma

Cost effectiveness of inhaled fluticasone propionate vs inhaled triamcinolone acetonide in the treatment of persistent asthma Cost effectiveness of inhaled fluticasone propionate vs inhaled triamcinolone acetonide in the treatment of persistent asthma Cost effectiveness of inhaled fluticasone propionate vs inhaled triamcinolone acetonide in the treatment of persistent asthma Stanford R H, Edwards L D, Rickard K A Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two inhaled corticosteroids, fluticasone propionate (FP) and triamcinolone acetonide (TA), were compared. The patients were treated with FP (250 microg twice daily) and placebo TA (two puffs four times daily) or TA (200 microg four times daily) and placebo FP (twice

2000 NHS Economic Evaluation Database.

103. Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis

Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis Stahl E, van Rompay W, Wang E C, Thomson D M Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Budesonide aqueous nasal spray and fluticasone propionate allergic spray in the treatment of perennial allergic rhinitis (PAR). Type of intervention Treatment. Economic study type Cost

2000 NHS Economic Evaluation Database.

104. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma.

A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2000 PedsCCM Evidence-Based Journal Club

105. Differences in lung bioavailability between different propellants for fluticasone propionate. (PubMed)

Differences in lung bioavailability between different propellants for fluticasone propionate. The lung bioavailability (as adrenal suppression) of fluticasone propionate was about twofold greater with chlorofluorocarbons than hydrofluoroalkane as propellant. Direct switching between formulations on a microg equivalent may therefore be inadvisable.

1999 Lancet

106. Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma

Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma Volmer T, Kielhorn A, Weber H H, Wiessmann K J Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Use of Fluticasone propionate (FP) or flunisolide (FL) in corticosteroid-naive patients with asthma of moderate severity. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Corticosteroid-naive

1999 NHS Economic Evaluation Database.

107. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children (Full text)

The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children Barnes N C, Thwaites R M, Price M J Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technologies were the use of fluticasone propionate (FP) and budesonide (Bud) in the treatment of patients suffering from asthma. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population consisted of adult

1999 NHS Economic Evaluation Database. PubMed

108. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. (PubMed)

Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. The efficacy of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease (COPD) remains controversial because of a lack of placebo-controlled studies. We compared the effect of inhaled fluticasone propionate with placebo in the treatment of patients with COPD.We used a randomised, double-blind, placebo (...) -controlled design. We enrolled from 13 European countries, New Zealand, and South Africa, 281 outpatient current or ex-smokers, aged between 50 and 75 years. They had a forced expiratory volume in 1 s (FEV1) of between 35% and 90% of predicted normal values, a ratio of FEV1 to forced vital capacity of 70% or less and bronchodilator reversibility of less than 15%, as well as a history of chronic bronchitis. Patients were randomly assigned fluticasone propionate 500 microg (n=142) or placebo (n=139) twice

1998 Lancet

109. Cost effectiveness of fluticasone and budesonide in patients with moderate asthma

Cost effectiveness of fluticasone and budesonide in patients with moderate asthma Cost effectiveness of fluticasone and budesonide in patients with moderate asthma Cost effectiveness of fluticasone and budesonide in patients with moderate asthma Steinmetz K O, Volmer T, Trautmann M, Kielhorn A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Inhaled fluticasone (metered dose inhaler) was compared to inhaled budesonide (Turbuhaler(R) in corticosteroid-naive patients with moderate asthma. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The authors did not define the study population. The study sample comprised patients enrolled in a multi-centre trial, who were aged between

1998 NHS Economic Evaluation Database.

110. Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care

Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care Price D B, Appleby J L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology Fluticasone propionate (FP) for the treatment of asthma. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Asthmatics registered at the authors' general practice office. Setting The practice setting was in the community. The economic analysis was carried out at the University of East Anglia, Norwich, UK. Dates to which data relate Effectiveness data were

1998 NHS Economic Evaluation Database.

111. A comparison of costs and efficacy of intranasal fluticasone propionate and terfenadine tablets for seasonal allergic rhinitis

A comparison of costs and efficacy of intranasal fluticasone propionate and terfenadine tablets for seasonal allergic rhinitis A comparison of costs and efficacy of intranasal fluticasone propionate and terfenadine tablets for seasonal allergic rhinitis A comparison of costs and efficacy of intranasal fluticasone propionate and terfenadine tablets for seasonal allergic rhinitis Kozma C M, Schulz R M, Sclar D A, Kral K M, Mackowiak J I Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of intranasal fluticasone propionate (200 micro g once daily) and terfenadine tablets (60 mg twice daily for fourteen days) in the treatment of patients with seasonal allergic rhinitis. Type of intervention Secondary prevention

1996 NHS Economic Evaluation Database.